Oxymetazoline Hydrochloride nasal drops is approved for the treatment of acute and chronic rhinitis, sinusitis and allergic rhinitis. Taurine eye drops is approved for the treatment of acute and chronic conjunctivitis.
The company is still aggressively seeking approval for other drugs with large market potential. By the end of 2008, the company will have a total 38 new drugs submitted to the SFDA approval.
Yan-qing Liu, chairman, CEO and director of China Sky One Medical, said: “We believe that the commercialization of these two products will provide a steady revenue for China Sky One and further improve our profitability in the years ahead.”